Clinical Neuropharmacology最新文献

{"title":"Drug-Induced Aseptic Meningitis: A 25-Year Systematic Review of Case Reports.","authors":"Madhusudan Prasad Singh, Riya Yadav, Juhi Singh","doi":"10.1097/WNF.0000000000000667","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000667","url":null,"abstract":"<p><strong>Objectives: </strong>This systematic review characterizes drug-induced aseptic meningitis (DIAM), a rare but clinically significant adverse drug reaction. The study synthesizes data from published case reports and case series to enhance diagnostic accuracy and guide management strategies.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in PubMed/MEDLINE, Scopus, Embase, Cochrane Library, ClinicalTrials.gov, and gray literature following PRISMA guidelines. Cases with detailed clinical and therapeutic data were included.</p><p><strong>Results: </strong>A total of 98 reports involving 108 patients were analyzed. The mean patient age was 47 years, with a slight female predominance (55%). The most commonly implicated drugs were nonsteroidal anti-inflammatory drugs, antibiotics, and monoclonal antibodies. Symptoms typically included headache (78%), fever (65%), and neck stiffness (56%), with severe neurological manifestations in 17%. Cerebrospinal fluid analysis showed pleocytosis in 65% and elevated protein in 60%. Magnetic resonance imaging findings were variable. Drug discontinuation led to symptom resolution in all cases, with corticosteroids used in severe presentations.</p><p><strong>Conclusions: </strong>DIAM mimics infectious meningitis, making early recognition critical. A thorough patient history, including medication exposure, is essential for diagnosis. This review underscores the need for clinician awareness to facilitate prompt identification and management. Future research should explore the immunopathogenesis and evidence-based treatment strategies for DIAM.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"49 1","pages":"11-40"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clopidogrel Loading Dose Strategy in Acute Ischemic Mild to Moderate Strokes and High-risk Transient Ischemic Attacks: Evaluation of the 90-day Risk of Stroke Recurrence and Bleeding Events.","authors":"Vanessa Ulloa, Kristen Curiel","doi":"10.1097/WNF.0000000000000662","DOIUrl":"10.1097/WNF.0000000000000662","url":null,"abstract":"<p><strong>Background: </strong>There is no direct guidance on the optimal clopidogrel loading dose (LD) strategy when starting dual antiplatelet therapy (DAPT) in patients diagnosed with mild to moderate acute ischemic stroke (AIS) or high-risk transient ischemic attacks (TIA).</p><p><strong>Objectives: </strong>Determine whether a specific clopidogrel LD influences the rate of recurrent stroke or bleeding events in patients with high-risk TIA or mild-moderate acute ischemic stroke.</p><p><strong>Methods: </strong>This is a multicenter, retrospective cohort study that included patients with mild-moderate AIS or high-risk TIA, treated with either a clopidogrel LD of 300 mg or 600 mg. The primary outcome was the incidence of recurrent ischemic stroke or TIA. The secondary outcomes assessed bleeding events, intracranial hemorrhage, myocardial infarction, mortality, and length of stay.</p><p><strong>Results: </strong>Recurrent stroke (P = 0.16) occurred in 3% and 7% of the 300 mg and 600 mg groups, respectively. Recurrent TIA (P = 0.58) occurred in 1% and 3% of the 300 mg and 600 mg groups, respectively. Severe bleeding (P = 0.09) and moderate bleeding (P = 0.67) between the 300 mg and 600 mg LD groups were insignificant.</p><p><strong>Conclusion: </strong>This study represents the first evaluation of the effects of the clopidogrel LD on recurrent ischemic strokes and TIA. While the optimal duration of 21 days of DAPT therapy has been established and recommended in guidelines, the optimal loading dose has yet to be established. These results highlight the need for additional research to evaluate the true outcomes associated with the use of a 300 or 600 mg LD within this patient population.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"49 1","pages":"44-49"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which is More Important to Enhance or Deteriorate Cognitive Functions in Older Adults With Major Cognitive Impairment: The Drug Burden Index or the Total Number of Medications?","authors":"Kubra Altunkalem Seydi, Fatma Sena Dost, Derya Kaya, Eral Idil, Mehmet Selman Ontan, Esra Ates Bulut, Ahmet Turan Isik","doi":"10.1097/WNF.0000000000000664","DOIUrl":"10.1097/WNF.0000000000000664","url":null,"abstract":"<p><strong>Objectives: </strong>To prevent the adverse effects, deprescribing is a structured approach aimed at reducing anticholinergic burden and improving clinical outcomes, particularly in those with cognitive impairment. The objective of this study was to ascertain the impact of alterations in the total number of medications and the Drug Burden Index (DBI) score on cognitive tests and Activity of Daily Living (ADL) scores during a 6-month follow-up period in older patients with major neurocognitive impairment.</p><p><strong>Methods: </strong>A total of 232 older patients with major neurocognitive impairment were enrolled in this study, which was retrospectively designed and followed up. The alterations in the total number of medications and the DBI scores were evaluated at baseline and at the end of the sixth month, which were compared with the changes in cognitive tests and ADL scores.</p><p><strong>Results: </strong>Comparing baseline and end-of-six-month Mini-Mental State Examination (MMSE) scores revealed a significant decrease in MMSE scores in patients with elevated DBI scores and those with increased medication intake ( P =0.001 and P =0.034, respectively). A subsequent comparison of the change in MMSE score across the groups revealed a significant decrease only among the group with decreased DBI score (Δ=0.45±3.29 and P <0.001). In the linear regression analysis, a 1-unit increase in DBI score and drug number was associated with a decrease in MMSE scores ( B : -0.245 vs. -0.197).</p><p><strong>Conclusions: </strong>The 6-month follow-up study demonstrated that deprescribing should prioritize the comprehensive evaluation of medication quantity and anticholinergic burden to enhance the efficacy of dementia care in older adults.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"50-56"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sulforaphane Adjunct to Methylphenidate for Attention-deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled Trial.","authors":"Farnaz Ghannadi, Ahmad Shamabadi, Mohammad Saleh Talebinejad, Ehsan Naseh, Ehsan Heidari, Sepideh Paknezhad, MohammadReza Mohammadi, Shahin Akhondzadeh","doi":"10.1097/WNF.0000000000000658","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000658","url":null,"abstract":"<p><strong>Objectives: </strong>Available treatment strategies for attention-deficit/hyperactivity disorder (ADHD) encounter significant limitations and, thus, necessitate novel therapeutic approaches. In this regard, this study investigated the effects of sulforaphane due to its neuroprotective, anti-inflammatory, and antioxidant properties.</p><p><strong>Methods: </strong>Seventy ADHD outpatients aged 6 to 11 were equally assigned to receive methylphenidate (0.3 to 1.5 mg/kg/d) plus either sulforaphane 30 mg/d or matched placebo for 8 weeks. The teacher and parent ADHD rating scale (ADHD-RS) was used to assess their symptoms at baseline and weeks 4 and 8. The patients were also evaluated for side effects.</p><p><strong>Results: </strong>Thirty-two patients in the sulforaphane group and 31 in the placebo group completed the study with comparable baseline demographic and clinical characteristics (Ps>0.05). There were significant time-treatment interaction effects on the ADHD-RS total, inattention, and hyperactivity-impulsivity scores rated by teachers (=0.245, 0.203, and 0.246, respectively) and parents (=0.265, 0.283, and 0.159, respectively). Affirmatively, their reductions were significantly greater in the sulforaphane group until the endpoint rated by teachers (Cohen ds=1.192, 1.055, and 1.220, respectively) and parents (Cohen's ds=1.344, 1.446, and 0.966, respectively). Better response to treatment (≥40% reduction in ADHD-RS total scores), robust improvement (≥50% reduction in ADHD-RS total scores), and remission (an ADHD-RS total score of ≤18) rates were obtained in the sulforaphane group until the endpoint (Ps<0.001). The side effect frequencies were comparable between the groups (Ps>0.05).</p><p><strong>Conclusions: </strong>Sulforaphane adjunct to methylphenidate was beneficial for inattention, hyperactivity-impulsivity, and total symptoms of children with ADHD safely and tolerably.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"48 6","pages":"181-187"},"PeriodicalIF":1.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moby Dick Supports an Ethological Model of Social Behavior, Socio-Cognition and Social Communication: Do von Economo-like Neurons Play a Role?","authors":"Stephen I Deutsch, Jessica A Burket, Jeffrey Elikan, Matthew Mya, David R Spiegel","doi":"10.1097/WNF.0000000000000657","DOIUrl":"10.1097/WNF.0000000000000657","url":null,"abstract":"<p><p>Herman Melville's Moby-Dick or The White Whale is a literary classic and historical account of 19th-century American whaling. Depictions of New Bedford, Nantucket, and life aboard the Pequod capture the whaling industry. Readers experience the whale hunt from sighting atop the ship's masts with shouts of \"Thar she blows!\" to excision of blubber and extraction of oil. Relationships are described, such as Ishmael, the novel's narrator, and Queequeg, a Pacific Islander harpooner reared as a prince among idolatrous cannibals. Captain Ahab's monomaniacal pursuit of Moby Dick, his hated nemesis, is the book's major plot. The novel's story is interrupted with descriptions of Sperm Whale anatomy and scattered observations of its behavior. Sperm Whales are social mammals, possessing the largest brain of all mammalian species, and capable of complex socio-cognitive computations and social communication. Sperm Whales use socially learned vocalization codas to \"identify\" matrilineally-defined social groups and \"non-identity codas\" to communicate between different social units sharing overlapping ocean habitats. Interestingly, Sperm Whales possess neurons morphologically similar to von Economo neurons (VENs) found in humans and other hominids. In higher primates, VENs support social behavior, higher socio-cognitive functions, and social communication. Thus, questions arise as to whether these morphologically similar \"von Economo-like\" neurons in Sperm Whales represent convergent evolution supporting complex socio-cognitive computations and social communication. In summary, Sperm Whales are an ethological model of social behavior, socio-cognitive functioning and social communication with translational relevance for man.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"212-219"},"PeriodicalIF":1.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric Adverse Events Associated With Dihydropyridine Calcium Channel Blockers: A Pharmacovigilance Study Based on FAERS Database.","authors":"Huafeng Jiang, Yimin Lin, Lidan Tu, Qingxia Hong","doi":"10.1097/WNF.0000000000000655","DOIUrl":"10.1097/WNF.0000000000000655","url":null,"abstract":"<p><strong>Objectives: </strong>Dihydropyridine calcium channel blockers (DHPCCBs) are widely employed in managing cardiovascular diseases. Although some studies suggest a potential link to psychiatric adverse events (PAEs), a systematic investigation is lacking.</p><p><strong>Methods: </strong>Adverse event reports for seven DHPCCBs marketed in the United States were collected from the FDA Adverse Event Reporting System (FAERS). PAEs were extracted from these reports and then performed using disproportionality analysis.</p><p><strong>Results: </strong>A total of 9164 PAEs associated with 7 DHPCCBs were identified, revealing 18 positive signal associations. For amlodipine, 18 positive signals were detected, with \"completed suicide,\" \"suicide attempt,\" and \"mental status changes\" being the most frequent. In contrast, nifedipine showed only 2 positive signals, which overlapped with amlodipine. No positive signals were found for the remaining five DHPCCBs. PAEs typically occur within the first 30 days of treatment. After adjusting for sex and age, 13 positive signals remained, 11 of which were related to suicidal behaviors.</p><p><strong>Conclusions: </strong>The disproportionality analysis identified signal associations between DHPCCBs and PAEs. These findings should be interpreted as hypothesis-generating signals requiring further validation through controlled studies. Clinicians may consider monitoring psychiatric symptoms in high-risk patients, particularly given the conflicting evidence from previous studies.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12610910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure-guided Docking of Benzene-1,3-Disulfonic Acid to the ApoE-HSPG Binding Site at Arginine 136 as a Christchurch-mimetic Therapeutic Strategy for Alzheimer Disease.","authors":"Steven Lehrer, Peter H Rheinstein","doi":"10.1097/WNF.0000000000000649","DOIUrl":"10.1097/WNF.0000000000000649","url":null,"abstract":"<p><strong>Objectives: </strong>The APOΕ3 Christchurch (APOΕ3Ch) variant, characterized by an R136S substitution, confers protection against Alzheimer disease (AD) by reducing apolipoprotein E (ApoE) binding to heparan sulfate proteoglycans (HSPGs), thereby limiting tau propagation. While antibody-based strategies mimicking this variant have shown promise, small-molecule approaches to disrupt the ApoE-HSPG interaction remain underexplored.</p><p><strong>Methods: </strong>We conducted a structure-guided molecular docking study targeting the ApoE HSPG-binding domain centered on Arg136, using AutoDock Vina within the SAMSON platform. The ligand benzene-1,3-disulfonic acid tiron, a small, anionic molecule with structural similarity to sulfated glycosaminoglycans, was docked to the cationic surface of ApoΕ3. Binding affinity, interaction pose, and root-mean-square deviation (RMSD) were assessed. Pharmacokinetic and toxicity predictions were performed using the pkCSM web server.</p><p><strong>Results: </strong>Benzene-1,3-disulfonic acid exhibited strong binding to the Arg136-containing pocket with a top docking score of -5.93 kcal/mol and an estimated inhibition constant (Ki) of 44.6 µmol. The top-ranked pose revealed stabilizing electrostatic interactions and hydrogen bonds with Arg136 and neighboring basic residues. pkCSM profiling predicted poor oral absorption and limited blood-brain barrier permeability, but a favorable safety profile, including no predicted hepatotoxicity, hERG inhibition (cardiac toxicity), or mutagenicity.</p><p><strong>Conclusions: </strong>These findings establish the feasibility of targeting the ApoE-HSPG interface with small molecules and identify benzene-1,3-disulfonic acid as a candidate Christchurch mimetic. While pharmacokinetic limitations preclude systemic use, intranasal delivery or ligand optimization may overcome brain access barriers. This study provides a foundation for developing novel small-molecule therapeutics to disrupt ApoE-mediated tau pathology in AD.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Modeling and Clinical Evaluation of Adverse Factors in Postherpetic Neuralgia Treated With Botulinum Toxin Type A: A Randomized Controlled Trial.","authors":"Mingfu Zheng, Lanrui Zeng, Li Ma","doi":"10.1097/WNF.0000000000000654","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000654","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to evaluate the efficacy of Botulinum toxin type A (BTX-A) in patients with postherpetic neuralgia (PHN) and to identify key prognostic factors associated with treatment response.</p><p><strong>Methods: </strong>This prospective, randomized controlled trial enrolled patients with PHN from November 2023 to January 2024. Sixty patients were randomized into 2 groups: the BTX-A group (standard care plus BTX-A injections) and the control group (standard care alone). The primary outcome was the change in pain intensity, assessed using the Visual Analog Scale (VAS) before and after treatment. Secondary outcomes included changes in inflammatory factor levels, the use of analgesics, and the occurrence of adverse events.</p><p><strong>Results: </strong>Compared with the control group, the BTX-A group showed significantly lower VAS scores and decreased inflammatory markers (P<0.001). After 1 month, the frequency of analgesic use decreased in both groups (P<0.001), but there was no difference between the groups. Multivariate logistic regression results showed that BTX-A was the only significant factor associated with pain reduction in PHN patients (P<0.001). Cox regression prognostic model results identified Gabapentin frequency, IL-6, and C-reactive protein as significant predictors of BTX-A treatment response (P<0.05). ROC analysis further showed that IL-6 was a strong predictor of BTX-A treatment response (AUC=0.804, P=0.034). Adverse events were rare and similar between groups.</p><p><strong>Conclusions: </strong>BTX-A may offer benefit in relieving pain and reducing inflammation in PHN patients compared with standard treatment, and IL-6 may be a strong predictor of efficacy.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Levetiracetam Cost on Epilepsy in a Resource-limited Country.","authors":"Xin-Yi Choon, Pek-Jing Soh, Nur Athirah Hassan, Kheng-Seang Lim, Hong-Gee Lee, Si-Lei Fong, Zhi-Qian Ong, Xuen Yu","doi":"10.1097/WNF.0000000000000656","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000656","url":null,"abstract":"<p><strong>Objectives: </strong>High treatment costs remain a major barrier for people with epilepsy (PWE), leading to significant treatment gaps. At the University of Malaya Medical Centre (UMMC), levetiracetam (LEV) is sold at a retail price (self-paying), but some patients receive subsidization. This study aimed to study the impact of medication costs on adherence, dosing, and quality of life among self-paying versus subsidized patients.</p><p><strong>Methods: </strong>This cross-sectional study was conducted at a tertiary care center in Kuala Lumpur, Malaysia. A structured questionnaire was used to assess the medication adherence, dosing, and quality of life among patients prescribed LEV, incorporating the Malaysian Medication Adherence Scale (MALMAS) and the Quality of Life in Epilepsy Inventory (QOLIE-31).</p><p><strong>Results: </strong>Among the 172 respondents, those under the subsidization scheme (86, 50%) had a higher mean maximum dose (2055.2 mg vs. 1688.4 mg, P=0.013) and were less likely to reduce LEV intake due to cost concerns (7.7% vs. 23.7%, P=0.021). In the self-paying group, more patients had low adherence (23.3% vs. 17.6%), the seizure-free rate was lower (22.1% vs. 29.1%), and the mean QOLIE-31 score was lower (60.5 vs. 62.4) than the subsidized group, but the differences were not statistically significant.</p><p><strong>Conclusions: </strong>Financial support is crucial in optimizing LEV dosing and adherence, with subsidized patients receiving higher doses and being less likely to reduce intake due to cost.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review.","authors":"Jaime Moreno-Chaparro, Gabriela Castañeda-Millán, Javier Eslava Schmalbach","doi":"10.1097/WNF.0000000000000653","DOIUrl":"10.1097/WNF.0000000000000653","url":null,"abstract":"<p><strong>Objective: </strong>Due to the boom in the use of certain psychedelics in different neuropsychiatric conditions, the objective was to synthesize the available information on the use of psilocybin (a psychedelic) in the population with autism spectrum disorder (ASD; a developmental neuropsychiatric condition).</p><p><strong>Methods: </strong>Scoping review. Question framework: Population: people with ASD-Concept: Psilocybin-Context: use, prescription, outcomes and pharmacological variables. The databases Medline (Pubmed), EMBASE, SCOPUS, LILACS, Web of Science and additional resources were searched until June 2024. Controlled and free terms combined with Boolean operators were used to find documents in English, Spanish and Portuguese. Screening was performed by title and abstract, full text and extraction independently by two reviewers. The analysis was descriptive and with emphasis on drug use. Protocol was registered in OSF (DOI code: 10.17605/OSF.IO/GPBVZ).</p><p><strong>Results: </strong>Four studies were included. Indications for psilocybin prescription in ASD patients were related to cognitive rigidity, exacerbated fear, behavioral/social difficulties, and inability to generate mental imagery. Two studies mentioned specific psilocybin administration, identifying microdoses and dosing intervals. Results were grouped into increased empathy and emotionality/sociability, reduction of symptoms associated with their condition or comorbidity and changes compared with other populations. All the studies were of acceptable quality with low evidence level.</p><p><strong>Conclusions: </strong>Descriptive findings of a therapeutic signal were observed in some subjects with ASD at low doses, not associated with toxic or disruptive effects. As restrictions on psilocybin use are lifted, studies with a higher level of evidence should be conducted.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"151-157"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}